DGX
QUEST DIAGNOSTICS INC
$197.21
-1.54%
$21.8B
No data for this timeframe.
Vol
Market Cap$21.8B
Cap SizeLarge Cap
Analyst ConsensusBuy (54%)
Inst. Holders9 funds
Inst. Value$4.1B
Inst. Activity2 buys / 0 sells
Insider Activity0B / 11S
Insider Net $-$7.1M
Reddit Sentiment56° Neutral
SEC Reports5
Recent Activity
Jun 4, 2026
Insider
KUPPUSAMY KARTHIK sold 3,320 shares
SVP, Clinical Solutions @ $127.73 ($424.0K)
Jun 4, 2026
Insider
KUPPUSAMY KARTHIK sold 8,147 shares
SVP, Clinical Solutions @ $200.00 ($1.6M)
Jun 4, 2026
Insider
KUPPUSAMY KARTHIK sold 3,320 shares
SVP, Clinical Solutions @ $127.73 ($424.0K)
May 18, 2026
dark_pool
Dark Pool: DGX — 1.2M shares, 36,146 trades
Week starting 2026-05-18. Total ATS volume: 1,210,273 shares across 36,146 trades.
May 8, 2026
SEC
Quest Diagnostics issued $500M of 5.000% senior notes due 2036, a routine debt refinancing/capital raise. The notes are
8-K — Impact 2/10
Apr 21, 2026
SEC
Quest Diagnostics reported strong Q1 2026 results with revenue of $2.90 billion (up 9.2% YoY) and reported EPS of $2.24
8-K — Impact 8/10
Mar 11, 2026
SEC
Three Quest Diagnostics executives sold shares in a coordinated open-market transaction on March 5, 2026, totaling appro
CLUSTER — Impact 7/10
Inst.
NORGES BANK — NEW
1,322,663 shares ($229.5M)
Price Targets
$223.44
+9.2% upside
Buy
Current $204.53
Low $184.00
Median $225.00
High $245.00
16 analysts
$184.00
$245.00
Analyst Ratings
6Strong Buy
7Buy
11Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 22, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| Apr 22, 2026 | Baird | MAINTAIN | Neutral → Neutral |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 22, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| Apr 8, 2026 | Evercore ISI Group | MAINTAIN | In-Line → In-Line |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.82 ▼ -1.5% | $2.75 — $2.91 | 8% YoY | 14 |
| Next Q | $2.80 | $2.74 — $2.92 | 8% YoY | 14 |
| Current FY | $10.77 ▲ +1.3% | $10.55 — $11.11 | 9% YoY | 17 |
| Next FY | $11.67 ▲ +1.6% | $11.33 — $12.30 | 8% YoY | 17 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.5B | — |
| MORGAN STANLEY | $467.4M | — |
| WELLS FARGO & COMPANY/MN | $307.0M | — |
| BANK OF AMERICA CORP | $281.6M | ADD |
| NORGES BANK | $229.5M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | KUPPUSAMY KARTHIK | M | $424.0K |
| Jun 4, 2026 | KUPPUSAMY KARTHIK | SELL | $1.6M |
| Jun 4, 2026 | KUPPUSAMY KARTHIK | M | $424.0K |
| Jun 1, 2026 | Davis J. | SELL | $1.9M |
| May 20, 2026 | PFEIFFER GARY | A | $0.00 |
Reddit Sentiment
56°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $4.1B total value (23,841,636 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, WELLS. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 14,392,082 | $2.5B | 60.5% | — |
| 2 | MORGAN STANLEY | 2,693,568 | $467.4M | 11.3% | — |
| 3 | WELLS FARGO & COMPANY/MN | 1,769,093 | $307.0M | 7.4% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 1,622,938 | $281.6M | 6.8% | ADD +36.3% |
| 5 | NORGES BANK | 1,322,663 | $229.5M | 5.6% | NEW |
| 6 | FMR LLC | 1,202,254 | $208.6M | 5.1% | ADD +25.9% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 751,054 | $130.3M | 3.2% | NEW |
| 8 | TWO SIGMA INVESTMENTS, LP | 47,984 | $8.3M | 0.2% | NEW |
| 9 | Olstein Capital Management, L.P. | 40,000 | $6.9K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,322,663 | — | $229.5M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 47,984 | — | $8.3M | 2025-Q4 |
| UBS Group AG | TRIM | 978,481 | 664,290 | -32.1% | $126.6M | 2025-Q3 |
| NORGES BANK | EXIT | 1,325,624 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,173,203 | 1,599,602 | +36.3% | $287.3M | 2025-Q2 |
| NORGES BANK | NEW | — | 1,325,624 | — | $238.1M | 2025-Q2 |
| FMR LLC | ADD | 981,350 | 1,235,394 | +25.9% | $221.9M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 10,539 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | EXIT | 120,400 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 92,500 | 310,843 | +236.0% | $52.6M | 2025-Q1 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | TRIM | 304,481 | 120,400 | -60.5% | $20.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 21,889 | 10,539 | -51.9% | $1.8M | 2025-Q1 |
| NORGES BANK | EXIT | 1,271,528 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 376,511 | 964,989 | +156.3% | $145.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 867,533 | 92,500 | -89.3% | $14.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 38,100 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 708,100 | — | $109.9M | 2024-Q3 |
18 unique insiders with 11 transactions. Net insider value: -$7.1M ($0.00 bought, $7.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M | 3,320 | $127.73 | $424.0K |
| Jun 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | SELL | 8,147 | $200.00 | $1.6M |
| Jun 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M | 3,320 | $127.73 | $424.0K |
| Jun 1, 2026 | Davis J. E. | CEO and President | SELL | 10,000 | $194.14 | $1.9M |
| May 20, 2026 | PFEIFFER GARY M | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | Lassiter Wright III | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | MORRISON DENISE M | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | RING TIMOTHY M | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | MAIN TIMOTHY L | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | Doi Tracey | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | WENTWORTH TIMOTHY C | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | Diaz Luis | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | Gregg Vicky B | Director | A | 1,142 | $0.00 | $0.00 |
| May 20, 2026 | CARTER ROBERT B | Director | A | 1,142 | $0.00 | $0.00 |
| Apr 20, 2026 | CARTER ROBERT B | Director | L | 7 | $194.70 | $1.4K |
| Apr 20, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | L | 37 | $194.70 | $7.2K |
| Apr 20, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | 39 | $194.70 | $7.6K |
| Apr 20, 2026 | Lassiter Wright III | Director | L | 6 | $194.70 | $1.2K |
| Apr 20, 2026 | Gregg Vicky B | Director | A | 68 | $194.70 | $13.2K |
| Apr 20, 2026 | Plewman Patrick | SVP for Diagnostic Services | L | 49 | $194.70 | $9.5K |
| Apr 20, 2026 | SAMAD SAM | Executive Vice President & CFO | A | 108 | $194.70 | $21.0K |
| Apr 1, 2026 | WENTWORTH TIMOTHY C | Director | A | 198 | $0.00 | $0.00 |
| Mar 9, 2026 | WENTWORTH TIMOTHY C | Director | A | 215 | $0.00 | $0.00 |
| Mar 5, 2026 | Plewman Patrick | SVP for Diagnostic Services | SELL | 2,855 | $206.21 | $588.7K |
| Mar 5, 2026 | Doherty Catherine T. | EVP, Regional Businesses | SELL | 5,558 | $206.21 | $1.1M |
| Mar 5, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | SELL | 3,878 | $206.21 | $799.7K |
| Mar 4, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | A | 1,473 | $204.86 | $301.8K |
| Mar 4, 2026 | Davis J. E. | CEO and President | A | 51,652 | $204.86 | $10.6M |
| Mar 4, 2026 | Plewman Patrick | SVP for Diagnostic Services | A | 5,682 | $204.86 | $1.2M |
| Mar 4, 2026 | SAMAD SAM | Executive Vice President & CFO | A | 13,947 | $204.86 | $2.9M |
| Mar 4, 2026 | Doherty Catherine T. | EVP, Regional Businesses | A | 11,364 | $204.86 | $2.3M |
| Mar 4, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | A | 5,682 | $204.86 | $1.2M |
| Mar 4, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | 7,232 | $204.86 | $1.5M |
| Mar 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | 6,200 | $204.86 | $1.3M |
| Mar 3, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | SELL | 526 | $207.73 | $109.3K |
| Mar 3, 2026 | Doherty Catherine T. | EVP, Regional Businesses | SELL | 632 | $207.73 | $131.3K |
| Mar 3, 2026 | Plewman Patrick | SVP for Diagnostic Services | SELL | 410 | $207.73 | $85.2K |
| Mar 2, 2026 | Plewman Patrick | SVP for Diagnostic Services | F | 230 | $204.86 | $47.1K |
| Mar 2, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | F | 188 | $204.86 | $38.5K |
| Mar 2, 2026 | Doherty Catherine T. | EVP, Regional Businesses | F | 648 | $204.86 | $132.7K |
| Mar 2, 2026 | Davis J. E. | CEO and President | F | 2,968 | $204.86 | $608.0K |
| Mar 2, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | 288 | $204.86 | $59.0K |
| Mar 2, 2026 | SAMAD SAM | Executive Vice President & CFO | F | 869 | $204.86 | $178.0K |
| Mar 2, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | 205 | $204.86 | $42.0K |
| Mar 2, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | F | 88 | $204.86 | $18.0K |
| Feb 19, 2026 | Plewman Patrick | SVP for Diagnostic Services | SELL | 958 | $204.83 | $196.2K |
| Feb 19, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | SELL | 1,111 | $204.83 | $227.6K |
| Feb 19, 2026 | Doherty Catherine T. | EVP, Regional Businesses | SELL | 1,433 | $204.83 | $293.5K |
| Feb 18, 2026 | Plewman Patrick | SVP for Diagnostic Services | A | 1,952 | $0.00 | $0.00 |
| Feb 18, 2026 | Plewman Patrick | SVP for Diagnostic Services | F | 244 | $210.01 | $51.2K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.6/10.
NEUTRAL
8-K
2/10
Quest Diagnostics issued $500M of 5.000% senior notes due 2036, a routine debt refinancing/capital r
May 8, 2026
BULLISH
8-K
8/10
Quest Diagnostics reported strong Q1 2026 results with revenue of $2.90 billion (up 9.2% YoY) and re
Apr 21, 2026
BEARISH
CLUSTER
7/10
Three Quest Diagnostics executives sold shares in a coordinated open-market transaction on March 5,
Mar 11, 2026
NEUTRAL
CLUSTER
3/10
Quest Diagnostics insiders saw a mix of non-cash award and tax withholding events alongside modest o
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
Seven executives at Quest Diagnostics executed tax withholding transactions, surrendering shares wor
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (54% buy). Based on 24 analysts: 6 strong buy, 7 buy, 11 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$223.44 mean target
+9.2% upside
Buy (2.11)
$184.00 Low
$245.00 High
| Metric | Value |
|---|---|
| Current Price | $204.53 |
| Target Low | $184.00 |
| Target Mean | $223.44 |
| Target Median | $225.00 |
| Target High | $245.00 |
| # Analysts | 16 |
| Recommendation | Buy (2.11) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.82 | $2.75 | $2.91 | 7.7% | -1.5% | 2↑ 10↓ | $3.0B | 7.7% | 14 |
| Next Q 2026-09-30 |
$2.80 | $2.74 | $2.92 | 7.8% | +0.2% | 4↑ 7↓ | $3.0B | 6.9% | 14 |
| Current FY 2026-12-31 |
$10.77 | $10.55 | $11.11 | 9.3% | +1.3% | 16↑ 0↓ | $11.9B | 7.4% | 17 |
| Next FY 2027-12-31 |
$11.67 | $11.33 | $12.30 | 8.4% | +1.6% | 17↑ 0↓ | $12.4B | 4.4% | 17 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.823 | |
| 7d ago | $2.823 | -0.000 |
| 30d ago | $2.866 | -0.043 |
| 60d ago | $2.863 | -0.041 |
| 90d ago | $2.850 | -0.027 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 22, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Apr 22, 2026 | Baird | MAINTAIN | Neutral | Neutral |
| Apr 22, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 22, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Apr 8, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Feb 12, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 11, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Feb 11, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Feb 11, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Feb 11, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 11, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| May 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Apr 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Mar 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Feb 1, 2026 | 6 | 7 | 11 | 0 | 0 | 54% | |
| Jan 1, 2026 | 6 | 6 | 12 | 0 | 0 | 50% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
56°
Neutral
Bearish
Neutral
Bullish
5 mentions
1 bullish
0 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 16, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 16, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 18, 2026
dark_pool
Dark Pool: DGX — 1.2M shares, 36,146 trades
Week starting 2026-05-18. Total ATS volume: 1,210,273 shares across 36,146 trades.
May 11, 2026
dark_pool
Dark Pool: DGX — 1.1M shares, 38,201 trades
Week starting 2026-05-11. Total ATS volume: 1,057,435 shares across 38,201 trades.
May 8, 2026
short_interest
FTD: DGX — 2,927 shares ($0.6M) failed to deliver
Settlement: 20260508, Price: $190.84, FTD Value: $558,588.68, QUEST DIAGNOSTICS INC.
May 4, 2026
dark_pool
Dark Pool: DGX — 1.0M shares, 39,436 trades
Week starting 2026-05-04. Total ATS volume: 1,046,653 shares across 39,436 trades.
Apr 27, 2026
dark_pool
Dark Pool: DGX — 1.5M shares, 46,440 trades
Week starting 2026-04-27. Total ATS volume: 1,489,012 shares across 46,440 trades.
Apr 22, 2026
short_volume
Short Volume: DGX — 67.1% short (0.4M / 0.6M)
Short: 412,533 | Exempt: 0 | TRF Vol: 614,531 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
earnings_calendar
DGX Q1 2026 Earnings Before Market Open — 2026-04-21
Apr 20, 2026
dark_pool
Dark Pool: DGX — 2.9M shares, 64,249 trades
Week starting 2026-04-20. Total ATS volume: 2,906,866 shares across 64,249 trades.
Apr 20, 2026
short_volume
Short Volume: DGX — 68.5% short (0.6M / 0.8M)
Short: 570,352 | Exempt: 0 | TRF Vol: 832,866 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
dark_pool
Dark Pool: DGX — 1.3M shares, 42,485 trades
Week starting 2026-04-13. Total ATS volume: 1,270,659 shares across 42,485 trades.
Apr 6, 2026
dark_pool
Dark Pool: DGX — 1.2M shares, 35,214 trades
Week starting 2026-04-06. Total ATS volume: 1,245,502 shares across 35,214 trades.
Mar 30, 2026
dark_pool
Dark Pool: DGX — 0.8M shares, 26,170 trades
Week starting 2026-03-30. Total ATS volume: 815,434 shares across 26,170 trades.
Mar 26, 2026
short_interest
FTD: DGX — 2,598 shares ($0.5M) failed to deliver
Settlement: 20260326, Price: $196.46, FTD Value: $510,403.08, QUEST DIAGNOSTICS INC.
Mar 23, 2026
short_interest
FTD: DGX — 16,937 shares ($3.3M) failed to deliver
Settlement: 20260323, Price: $195.26, FTD Value: $3,307,118.62, QUEST DIAGNOSTICS INC.
Mar 23, 2026
dark_pool
Dark Pool: DGX — 1.1M shares, 34,780 trades
Week starting 2026-03-23. Total ATS volume: 1,145,747 shares across 34,780 trades.